Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease

Authors not listed

Eli Lilly and Company · 2026

Abstract

The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2026). A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease. <em>Eli Lilly and Company</em>. https://clinicaltrials.gov/study/NCT07787169
Vancouver
Anonymous. A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease. Eli Lilly and Company. 2026.
BibTeX
@misc{anon2026AMaste, title = {A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease}, author = {Anonymous}, journal = {Eli Lilly and Company}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings